CD8A and hepatocellular carcinoma: To evaluate whether the anti-tumor effect of sorafenib promoted by Efm was dependent on CD8+ T cell activity, we compared the anti-tumor activity of sorafenib in the presence or absence of CD8+ T cells by using an anti-mouse CD8 antibody in the hepa1-6 HCC model and the antibody effectiveness was detected by flow cytometry (Figure 4b).